Hematuria
41
6
6
16
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.8%
4 terminated out of 41 trials
80.0%
-6.5% vs benchmark
12%
5 trials in Phase 3/4
6%
1 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (41)
Bladder Cancer Screening Trial
Efficacy and Utility of Cxbladder Tests in Hematuria Patients
RADA16 for Aquablation Day Case
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
A Study of Ward Admissions for Haematuria
Bladder EpiCheck European Haematuria Study
Study on Risk Assessment for Patients With Microscopic Hematuria (Non-Visible Blood in Urine) Using a Urine Marker Test
Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors
Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA
Clinical and Laboratory Patterns of Pediatric Gross Hematuria
Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria
Urine DNA Methylation Detection for Hematuria Evaluation
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
Multimedia Information for Patients With Renal Biopsy
Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder